Literature DB >> 22435709

The impact of insulin administration during the mixed meal tolerance test.

R E J Besser1, A G Jones, T J McDonald, B M Shields, B A Knight, A T Hattersley.   

Abstract

AIMS: The mixed meal tolerance test is the gold standard measure of endogenous insulin secretion. Practical issues limit the routine clinical use of this test, including omitting insulin prior to the ingestion of a high-carbohydrate liquid mixed meal, which can result in marked hyperglycaemia. We aimed to assess whether insulin omission is necessary during the mixed meal tolerance test and whether fasting C-peptide was a practical alternative to the test.
METHODS: Ninety-one adults with insulin-treated diabetes (Type 1 n = 56, Type 2 n = 35) underwent two mixed meal tolerance tests; one standard without insulin and one with the patient's usual morning insulin.
RESULTS: The 90-min serum C-peptide was highly correlated in the standard mixed meal tolerance test and the test with insulin (r = 0.98, P < 0.0001). There was a 20% reduction in the peak C-peptide value when insulin was given {test with insulin [0.39 (0.01-1.16) vs. test without insulin 0.48 (0.01-1.36) nmol/l, P = 0.001]}, but the original serum C-peptide cut-off for significant endogenous insulin secretion (≥ 0.2 nmol/l) still correctly classified 90/91 patients (98% sensitivity/100% specificity). Fasting serum C-peptide was highly correlated to 90-min serum C-peptide during the test (r = 0.97, P < 0.0001). A fasting serum C-peptide ≥ 0.07 nmol/l was the optimal cut-off (100% sensitivity and 97% specificity) for significant endogenous insulin secretion (defined as 90-min stimulated serum C-peptide ≥ 0.2 nmol/l).
CONCLUSIONS: Insulin omission may not always be necessary during a mixed meal tolerance test and fasting serum C-peptide may offer a practical alternative in insulin-treated patients.
© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22435709     DOI: 10.1111/j.1464-5491.2012.03649.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  11 in total

1.  Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic.

Authors:  S V Hope; B A Knight; B M Shields; A T Hattersley; T J McDonald; A G Jones
Journal:  Diabet Med       Date:  2016-05-26       Impact factor: 4.359

2.  C-peptide levels and the risk of diabetes and pre-diabetes among Chinese women with gestational diabetes.

Authors:  Ping Yin; Ping Shao; Huikun Liu; Weiqin Li; Leishen Wang; Jing Wang; Shuang Zhang; Junhong Leng; Nan Li; Huiguang Tian; Xilin Yang; Zhijie Yu; Gang Hu
Journal:  J Diabetes Complications       Date:  2017-08-17       Impact factor: 2.852

3.  Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors.

Authors:  Richard A Oram; Timothy J McDonald; Beverley M Shields; Michelle M Hudson; Maggie H Shepherd; Suzanne Hammersley; Ewan R Pearson; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2014-12-17       Impact factor: 19.112

4.  Insulin initiation: bringing objectivity to choice.

Authors:  Sanjay Kalra; Yashdeep Gupta
Journal:  J Diabetes Metab Disord       Date:  2015-03-25

Review 5.  The clinical utility of C-peptide measurement in the care of patients with diabetes.

Authors:  A G Jones; A T Hattersley
Journal:  Diabet Med       Date:  2013-07       Impact factor: 4.359

6.  Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis.

Authors:  Suzy V Hope; Sophie Wienand-Barnett; Maggie Shepherd; Sophie M King; Charles Fox; Kamlesh Khunti; Richard A Oram; Bea A Knight; Andrew T Hattersley; Angus G Jones; Beverley M Shields
Journal:  Br J Gen Pract       Date:  2016-04-14       Impact factor: 5.386

7.  Normal meal tolerance test is preferable to the glucagon stimulation test in patients with type 2 diabetes that are not in a hyperglycemic state: Comparison with the change of C-peptide immunoreactivity.

Authors:  Youhei Fujioka; Tsuyoshi Okura; Keisuke Sumi; Kazuhisa Matsumoto; Kyoko Shoji; Risa Nakamura; Kazuhiko Matsuzawa; Shoichiro Izawa; Masahiko Kato; Shinichi Taniguchi; Kazuhiro Yamamoto
Journal:  J Diabetes Investig       Date:  2017-06-19       Impact factor: 4.232

8.  Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.

Authors:  Angus G Jones; Timothy J McDonald; Beverley M Shields; Anita V Hill; Christopher J Hyde; Bridget A Knight; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2015-08-04       Impact factor: 19.112

9.  Frequent Monitoring of C-Peptide Levels in Newly Diagnosed Type 1 Subjects Using Dried Blood Spots Collected at Home.

Authors:  Ruben H Willemsen; Keith Burling; Peter Barker; Fran Ackland; Renuka P Dias; Julie Edge; Anne Smith; John Todd; Boryana Lopez; Adrian P Mander; Catherine Guy; David B Dunger
Journal:  J Clin Endocrinol Metab       Date:  2018-09-01       Impact factor: 5.958

10.  The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.

Authors:  Eleonora Seelig; James Howlett; Linsey Porter; Lucy Truman; James Heywood; Jane Kennet; Emma L Arbon; Katerina Anselmiova; Neil M Walker; Ravinder Atkar; Marcin L Pekalski; Ed Rytina; Mark Evans; Linda S Wicker; John A Todd; Adrian P Mander; Simon Bond; Frank Waldron-Lynch
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.